Research Progress of Cytokines in the Prognosis of Acute Myeloid Leukemia --Review.
10.19746/j.cnki.issn.1009-2137.2022.06.047
- Author:
Chun-Yan LIANG
1
;
Zeng-Zheng LI
1
;
Min WANG
1
;
Ya-Jie WANG
1
;
Tong-Hua YANG
2
Author Information
1. Department of Hematology, The Affiliated Hospital of Kunming University of Science and Technology, The First People's Hospital of Yunnan Province, Kunming 650500, Yunnan Province, China.
2. Department of Hematology, The Affiliated Hospital of Kunming University of Science and Technology, The First People's Hospital of Yunnan Province, Kunming 650500, Yunnan Province, China,E-mail: ynanblood@aliyun.com.
- Publication Type:Journal Article
- Keywords:
acute myeloid leukemia;
cytokine;
prognostic factor;
treatment
- MeSH:
Humans;
Cytokines;
Leukemia, Myeloid, Acute
- From:
Journal of Experimental Hematology
2022;30(6):1922-1926
- CountryChina
- Language:Chinese
-
Abstract:
At present, acute myeloid leukemia (AML) is mainly treated with combination medication, high-dose, and early intensification. The treatment has achieved good results, but the long-term treatment effect is still not satisfactory. Studies have shown that the different levels of cytokine expression in AML patients can help AML risk stratification, search for treatment directions and predict the prognosis. It has been confirmed that the expression of IL-1β, IL-6, TNF-α, and TGF-β1 are increased in AML patients, and they all indicate a poor prognosis. However, IL-8, IFN-γ, and CCL5 have great research value in chemotherapy resistance and improvement of treatment effect. This article reviews the research progress of cytokine biomarkers in the prognosis of AML patients.
